Gilead- Staying long
Technicals look fairly good, but perhaps slightly over-brought in the near term.
GILD's monster quarter helped the shares jolt upward and break through the medium-term downtrend that hit the stock after fears over margins for Harvoni & Sovaldi.
- Q1 Earnings: Decimated Revs & EPS
-Q1 Earnings:Margins not hit as badly as expected
-HIV & Nash mitigate one trick pony risk
-Shrewd management that has avoided expensive M&A, and has historically made excellent acquisition decisions (e.g. Pharmasset in 2011) If the recent moves into oncology by acquiring EpiTherapeutics prove to be anywhere near as -fruitful as Hep-C, shareholders will profit handsomely.
-Although the recent foray into Hep-B was unsuccessful, this is an area to look out for (huge growth opportunity)
GILD's monster quarter helped the shares jolt upward and break through the medium-term downtrend that hit the stock after fears over margins for Harvoni & Sovaldi.
- Q1 Earnings: Decimated Revs & EPS
-Q1 Earnings:Margins not hit as badly as expected
-HIV & Nash mitigate one trick pony risk
-Shrewd management that has avoided expensive M&A, and has historically made excellent acquisition decisions (e.g. Pharmasset in 2011) If the recent moves into oncology by acquiring EpiTherapeutics prove to be anywhere near as -fruitful as Hep-C, shareholders will profit handsomely.
-Although the recent foray into Hep-B was unsuccessful, this is an area to look out for (huge growth opportunity)
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.